Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA CALCINEURIN INHIBITORS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 DBMR MARKET POSITION GRID
2.8 VENDOR SHARE ANALYSIS
2.9 SECONDARY SOURCES
2.1 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
5 APAC DEPRESSION SCREENING MARKET: REGULATIONS
5.1 REGULATORY AUTHORITIES IN NORTH AMERICA.
5.1.1 U.S. FOOD AND DRUG ADMINISTRATION (FDA)
5.1.2 HEALTH CANADA
5.1.3 FEDERAL COMMISSION FOR THE PROTECTION AGAINST SANITARY RISKS (COFEPRIS) - MEXICO
5.2 REGULATORY AUTHORITIES IN EUROPE.
5.2.1 GERMANY:
5.2.2 UNITED KINGDOM:
5.2.3 FRANCE:
5.2.4 ITALY:
5.2.5 SPAIN:
5.3 REGULATORY AUTHORITIES IN ASIA-PACIFIC.
5.3.1 JAPAN:
5.3.2 CHINA:
5.3.3 INDIA:
5.3.4 SOUTH KOREA:
5.3.5 AUSTRALIA:
5.4 REGULATORY AUTHORITIES IN MIDDLE EAST AND AFRICA.
5.4.1 SAUDI ARABIA:
5.4.2 UNITED ARAB EMIRATES (UAE):
5.4.3 EGYPT:
5.4.4 SOUTH AFRICA:
5.5 REGULATORY AUTHORITIES IN SOUTH AMERICA.
5.5.1 BRAZIL:
5.5.2 ARGENTINA:
5.5.3 COLOMBIA:
5.5.4 CHILE:
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF AUTOIMMUNE DISEASES
6.1.2 INCREASING TRANSPLANTATION PROCEDURES
6.1.3 ADVANCEMENTS IN MEDICAL TECHNOLOGY
6.1.4 GOVERNMENT SUPPORT & FUNDING FOR TRANSPLANTS
6.2 RESTRAINTS
6.2.1 LIMITED EFFICACY FOR LONG-TERM USE OF CALCINEURIN INHIBITORS.
6.2.2 AVAILABILITY OF ALTERNATIVE IMMUNOSUPPRESSIVE THERAPIES.
6.3 OPPORTUNITIES
6.3.1 GROWING DEMAND FOR PERSONALIZED MEDICINE
6.3.2 GROWING GERIATRIC POPULATION
6.3.3 ADVANCEMENTS IN DRUG DELIVERY
6.4 CHALLENGES
6.4.1 COMPLEX DOSING AND MONITORING
6.4.2 HIGH COSTS
7 NORTH AMERICA CALCINEURIN INHIBITORS MARKET, BY DRUGS
7.1 OVERVIEW
7.2 TACROLIMUS
7.2.1 GENERIC
7.2.2 BRANDED
7.2.2.1 PROGRAF
7.2.2.2 ASTAGRAF XL
7.2.2.3 ENVARSUS XR
7.2.2.4 OTHER
7.2.2.4.1 CAPSULES
7.2.2.4.2 TABLETS
7.2.2.4.3 INJECTIONS
7.2.2.4.4 GRANULES FOR ORAL SUSPENSION
7.2.2.4.4.1 1 MG
7.2.2.4.4.2 0.5 MG
7.2.2.4.4.3 5 MG
7.2.2.4.4.4 OTHERS
7.2.2.4.4.5 ADULT
7.2.2.4.4.6 GERIATRIC
7.2.2.4.4.7 PEDIATRIC
7.3 CYCLOSPORINE
7.3.1 GENERIC
7.3.2 BRANDED
7.3.2.1 NEORAL
7.3.2.2 SANDIMMUNE
7.3.2.3 GENGRAF
7.3.2.4 OTHERS
7.3.2.4.1 CAPSULES
7.3.2.4.2 ORAL SOLUTION
7.3.2.4.3 INJECTION
7.3.2.4.4 OTHERS
7.3.2.4.4.1 100 MG
7.3.2.4.4.2 25 MG
7.3.2.4.4.3 50 MG
7.3.2.4.4.4 OTHERS
7.3.2.4.4.5 ADULT
7.3.2.4.4.6 PEDIATRIC
7.3.2.4.4.7 GERIATRIC
7.4 PIMECROLIMUS (TOPICAL CREAM)
7.4.1 GENERIC
7.4.2 BRANDED
7.4.2.1 ADULT
7.4.2.2 GERIATRIC
7.4.2.3 PEDIATRIC
7.5 VOCLOSPORIN (ORAL CAPSULE)
7.6 OTHERS
7.6.1 GENERIC
7.6.2 BRANDED
8 NORTH AMERICA CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE
8.1 OVERVIEW
8.2 GENERIC
8.2.1 POSTOPERATIVE IMMUNOSUPPRESSION
8.2.2 ATOPIC DERMATITIS
8.2.3 ULCERATIVE COLITIS
8.2.4 PSORIASIS
8.2.5 KERATOCONJUNCTIVITIS
8.2.6 OTHERS
8.3 BRANDED
8.3.1 POSTOPERATIVE IMMUNOSUPPRESSION
8.3.2 ATOPIC DERMATITIS
8.3.3 ULCERATIVE COLITIS
8.3.4 PSORIASIS
8.3.5 KERATOCONJUNCTIVITIS
8.3.6 OTHERS
9 NORTH AMERICA CALCINEURIN INHIBITORS MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 POSTOPERATIVE IMMUNOSUPPRESSION
9.3 ATOPIC DERMATITIS
9.4 ULCERATIVE COLITIS
9.5 PSORIASIS
9.6 KERATOCONJUNCTIVITIS
9.7 OTHERS
10 NORTH AMERICA CALCINEURIN INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
10.1 OVERVIEW
10.2 ORAL
10.2.1 CAPSULE
10.2.2 TABLET
10.2.3 SOLUTION
10.3 TOPICAL
10.4 PARENTERAL
10.5 OTHERS
11 NORTH AMERICA CALCINEURIN INHIBITORS MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 SPECIALTY CLINICS
11.4 HOME HEALTHCARE
11.5 ACADEMIC AND RESEARCH INSTITUTES
11.6 OTHERS
12 NORTH AMERICA CALCINEURIN INHIBITORS MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 HOSPITAL PHARMACY
12.3 RETAIL PHARMACY
12.4 ONLINE PHARMACY
12.5 OTHERS
13 NORTH AMERICA CALCINEURIN INHIBITOR MARKET, BY REGION
13.1 NORTH AMERICA
14 NORTH AMERICA CALCINEURIN INHIBITORS MARKET, COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
15 SWOT ANALYSIS
16 COMPANY PROFILES
16.1 ASTELLAS PHARMA US, INC.
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENT
16.2 CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENT
16.3 LUPIN
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENT
16.4 HUADONG MEDICINE CO.,LTD
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENT
16.5 VIATRIS INC.
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENT
16.6 APOTEX INC.
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENT
16.7 ABBVIE INC
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 RECENT DEVELOPMENT
16.8 ACCORD HEALTHCARE US.
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENT
16.9 ACTIZAPHARMA
16.9.1 COMPANY SNAPSHOT
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENT
16.1 ADVACARE PHARMA
16.10.1 COMPANY SNAPSHOT
16.10.2 PRODUCT PORTFOLIO
16.10.3 RECENT DEVELOPMENT
16.11 BIOCON
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENT
16.12 BAUSCH HEALTH COMPANIES INC.
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENT
16.13 CONCORD BIOTECH
16.13.1 COMPANY SNAPSHOT
16.13.2 REVENUE ANALYSIS
16.13.3 PRODUCT PORTFOLIO
16.13.4 RECENT DEVELOPMENT
16.14 DR. REDDY’S LABORATORIES
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVELOPMENT
16.15 GLENMARK PHARMACEUTICALS INC
16.15.1 COMPANY SNAPSHOT
16.15.2 REVENUE ANALYSIS
16.15.3 PRODUCT PORTFOLIO
16.15.4 RECENT DEVELOPMENT
16.16 LEO PHARMA INC.
16.16.1 COMPANY SNAPSHOT
16.16.2 PRODUCT PORTFOLIO
16.16.3 RECENT DEVELOPMENT
16.17 LIPELLA PHARMACEUTICALS, INC.
16.17.1 COMPANY SNAPSHOT
16.17.2 REVENUE ANALYSIS
16.17.3 PRODUCT PORTFOLIO
16.17.4 RECENT DEVELOPMENT
16.18 NOVARTIS AG
16.18.1 COMPANY SNAPSHOT
16.18.2 REVENUE ANALYSIS
16.18.3 PRODUCT PORTFOLIO
16.18.4 RECENT DEVELOPMENT
16.19 NOVALIQ GMBH
16.19.1 COMPANY SNAPSHOT
16.19.2 PRODUCT PORTFOLIO
16.19.3 RECENT DEVELOPMENT
16.2 PANACEA BIOTEC
16.20.1 COMPANY SNAPSHOT
16.20.2 REVENUE ANALYSIS
16.20.3 PRODUCT PORTFOLIO
16.20.4 RECENT DEVELOPMENT
16.21 PADAGIS
16.21.1 COMPANY SNAPSHOT
16.21.2 PRODUCT PORTFOLIO
16.21.3 RECENT DEVELOPMENT
16.22 RPG LIFE SCIENCES LIMITED
16.22.1 COMPANY SNAPSHOT
16.22.2 REVENUE ANALYSIS
16.22.3 PRODUCT PORTFOLIO
16.22.4 RECENT DEVELOPMENT
16.23 VELOXIS PHARMACEUTICALS, INC.
16.23.1 COMPANY SNAPSHOT
16.23.2 REVENUE ANALYSIS
16.23.3 PRODUCT PORTFOLIO
16.23.4 RECENT DEVELOPMENT
16.24 ZHAOKE OPHTHALMOLOGY LIMITED
16.24.1 COMPANY SNAPSHOT
16.24.2 REVENUE ANALYSIS
16.24.3 PRODUCT PORTFOLIO
16.24.4 RECENT DEVELOPMENT
16.25 ZAMBON COMPANY S.P.A.
16.25.1 COMPANY SNAPSHOT
16.25.2 PRODUCT PORTFOLIO
16.25.3 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
List of Table
TABLE 1 NORTH AMERICA CALCINEURIN INHIBITORS MARKET, BY DRUGS, 2018-2032 (USD MILLION)
TABLE 2 NORTH AMERICA TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 3 NORTH AMERICA TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 4 NORTH AMERICA BRANDED IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 5 NORTH AMERICA TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 6 NORTH AMERICA TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY STRENGTH, 2018-2032 (USD MILLION)
TABLE 7 NORTH AMERICA TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 8 NORTH AMERICA CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 9 NORTH AMERICA CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 10 NORTH AMERICA BRANDED IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 11 NORTH AMERICA CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 12 NORTH AMERICA CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY STRENGTH, 2018-2032 (USD MILLION)
TABLE 13 NORTH AMERICA CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 14 NORTH AMERICA PIMECROLIMUS (TOPICAL CREAM) IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 15 NORTH AMERICA PIMECROLIMUS (TOPICAL CREAM) IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 16 NORTH AMERICA PIMECROLIMUS (TOPICAL CREAM) IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 17 NORTH AMERICA VOCLOSPORIN (ORAL CAPSULE) IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 18 NORTH AMERICA OTHERS IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 19 NORTH AMERICA OTHERS IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 20 NORTH AMERICA CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 21 NORTH AMERICA GENERIC IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 22 NORTH AMERICA CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 23 NORTH AMERICA BRANDED IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 24 NORTH AMERICA CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 25 NORTH AMERICA CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 26 NORTH AMERICA POSTOPERATIVE IMMUNOSUPPRESSION IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032(USD MILLION)
TABLE 27 NORTH AMERICA ATOPIC DERMATITIS IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 28 NORTH AMERICA ULCERATIVE COLITIS IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 29 NORTH AMERICA PSORIASIS IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 30 NORTH AMERICA KERATOCONJUNCTIVITIS IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 31 NORTH AMERICA OTHERS IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 32 NORTH AMERICA OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 33 NORTH AMERICA ORAL IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032(USD MILLION)
TABLE 34 NORTH AMERICA ORAL IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 35 NORTH AMERICA TOPICAL IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 36 NORTH AMERICA PARENTRAL IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 37 NORTH AMERICA OTHERS IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 38 NORTH AMERICA CALCINEURIN INHIBITORS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 39 NORTH AMERICA HOSPITALS IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032(USD MILLION)
TABLE 40 NORTH AMERICA HOSPITALS IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 41 NORTH AMERICA HOSPITALS IN CALCINEURIN INHIBITORS MARKET, BY LEVEL, 2018-2032 (USD MILLION)
TABLE 42 NORTH AMERICA SPECIALTY CLINICS IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032(USD MILLION)
TABLE 43 NORTH AMERICA HOME HEALTHCARE IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032(USD MILLION)
TABLE 44 NORTH AMERICA ACADEMIC AND RESEARCH INSTITUTES IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032(USD MILLION)
TABLE 45 NORTH AMERICA OTHERS IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032(USD MILLION)
TABLE 46 NORTH AMERICA CALCINEURIN INHIBITORS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 47 NORTH AMERICA HOSPITAL PHARMACY IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032(USD MILLION)
TABLE 48 NORTH AMERICA RETAIL PHARMACY IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 49 NORTH AMERICA ONLINE PHARMACY IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 50 NORTH AMERICA OTHERS IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 51 NORTH AMERICA CALCINEURIN INHIBITORS MARKET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52 NORTH AMERICA CALCINEURIN INHIBITORS MARKET, BY DRUGS, 2018-2032 (USD MILLION)
TABLE 53 NORTH AMERICA TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 54 NORTH AMERICA BRANDED IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 55 NORTH AMERICA TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 56 NORTH AMERICA TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY STRENGTH, 2018-2032 (USD MILLION)
TABLE 57 NORTH AMERICA TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 58 NORTH AMERICA CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 59 NORTH AMERICA BRANDED IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 60 NORTH AMERICA CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 61 NORTH AMERICA CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY STRENGTH, 2018-2032 (USD MILLION)
TABLE 62 NORTH AMERICA CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 63 NORTH AMERICA PIMECROLIMUS (TOPICAL CREAM) IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 64 NORTH AMERICA PIMECROLIMUS (TOPICAL CREAM) IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 65 NORTH AMERICA CALCINEURIN INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 66 NORTH AMERICA ORAL IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 67 NORTH AMERICA OTHERS IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 68 NORTH AMERICA CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 69 NORTH AMERICA GENERIC IN CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 70 NORTH AMERICA BRANDED IN CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 71 NORTH AMERICA CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 72 NORTH AMERICA CALCINEURIN INHIBITORS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 73 NORTH AMERICA HOSPITALS IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 74 NORTH AMERICA HOSPITALS IN CALCINEURIN INHIBITORS MARKET, BY LEVEL, 2018-2032 (USD MILLION)
TABLE 75 NORTH AMERICA CALCINEURIN INHIBITORS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 76 U.S. CALCINEURIN INHIBITORS MARKET, BY DRUGS, 2018-2032 (USD MILLION)
TABLE 77 U.S. TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 78 U.S. BRANDED IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 79 U.S. TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 80 U.S. TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY STRENGTH, 2018-2032 (USD MILLION)
TABLE 81 U.S. TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 82 U.S. CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 83 U.S. BRANDED IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 84 U.S. CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 85 U.S. CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY STRENGTH, 2018-2032 (USD MILLION)
TABLE 86 U.S. CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 87 U.S. PIMECROLIMUS (TOPICAL CREAM) IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 88 U.S. PIMECROLIMUS (TOPICAL CREAM) IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 89 U.S. CALCINEURIN INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 90 U.S. ORAL IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 91 U.S. OTHERS IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 92 U.S. CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 93 U.S. GENERIC IN CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 94 U.S. BRANDED IN CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 95 U.S. CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 96 U.S. CALCINEURIN INHIBITORS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 97 U.S. HOSPITALS IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 98 U.S. HOSPITALS IN CALCINEURIN INHIBITORS MARKET, BY LEVEL, 2018-2032 (USD MILLION)
TABLE 99 U.S. CALCINEURIN INHIBITORS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 100 CANADA CALCINEURIN INHIBITORS MARKET, BY DRUGS, 2018-2032 (USD MILLION)
TABLE 101 CANADA TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 102 CANADA BRANDED IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 103 CANADA TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 104 CANADA TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY STRENGTH, 2018-2032 (USD MILLION)
TABLE 105 CANADA TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 106 CANADA CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 107 CANADA BRANDED IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 108 CANADA CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 109 CANADA CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY STRENGTH, 2018-2032 (USD MILLION)
TABLE 110 CANADA CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 111 CANADA PIMECROLIMUS (TOPICAL CREAM) IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 112 CANADA PIMECROLIMUS (TOPICAL CREAM) IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 113 CANADA CALCINEURIN INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 114 CANADA ORAL IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 115 CANADA OTHERS IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 116 CANADA CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 117 CANADA GENERIC IN CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 118 CANADA BRANDED IN CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 119 CANADA CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 120 CANADA CALCINEURIN INHIBITORS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 121 CANADA HOSPITALS IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 122 CANADA HOSPITALS IN CALCINEURIN INHIBITORS MARKET, BY LEVEL, 2018-2032 (USD MILLION)
TABLE 123 CANADA CALCINEURIN INHIBITORS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 124 MEXICO CALCINEURIN INHIBITORS MARKET, BY DRUGS, 2018-2032 (USD MILLION)
TABLE 125 MEXICO TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 126 MEXICO BRANDED IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 127 MEXICO TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 128 MEXICO TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY STRENGTH, 2018-2032 (USD MILLION)
TABLE 129 MEXICO TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 130 MEXICO CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 131 MEXICO BRANDED IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 132 MEXICO CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 133 MEXICO CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY STRENGTH, 2018-2032 (USD MILLION)
TABLE 134 MEXICO CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 135 MEXICO PIMECROLIMUS (TOPICAL CREAM) IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 136 MEXICO PIMECROLIMUS (TOPICAL CREAM) IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 137 MEXICO CALCINEURIN INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 138 MEXICO ORAL IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 139 MEXICO OTHERS IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 140 MEXICO CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 141 MEXICO GENERIC IN CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 142 MEXICO BRANDED IN CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 143 MEXICO CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 144 MEXICO CALCINEURIN INHIBITORS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 145 MEXICO HOSPITALS IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 146 MEXICO HOSPITALS IN CALCINEURIN INHIBITORS MARKET, BY LEVEL, 2018-2032 (USD MILLION)
TABLE 147 MEXICO CALCINEURIN INHIBITORS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
List of Figure
FIGURE 1 NORTH AMERICA CALCINEURIN INHIBITORS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA CALCINEURIN INHIBITORS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA CALCINEURIN INHIBITORS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA CALCINEURIN INHIBITORS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA CALCINEURIN INHIBITORS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA CALCINEURIN INHIBITORS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA CALCINEURIN INHIBITORS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA CALCINEURIN INHIBITORS MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 NORTH AMERICA CALCINEURIN INHIBITORS MARKET: SEGMENTATION
FIGURE 10 EXECUTIVE SUMMARY
FIGURE 11 STRATEGIC DECISIONS
FIGURE 12 FIVE SEGMENTS COMPRISE THE NORTH AMERICA CALCINEURIN INHIBITORS MARKET, BY DRUGS
FIGURE 13 RISING PREVALENCE OF AUTOIMMUNE DISEASES IS DRIVING THE GROWTH OF THE NORTH AMERICA CALCINEURIN INHIBITORS MARKET FROM 2025 TO 2032
FIGURE 14 THE TACROLIMUS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA CALCINEURIN INHIBITORS MARKET IN 2025 AND 2032
FIGURE 15 DROC ANALYSIS
FIGURE 16 NORTH AMERICA CALCINEURIN INHIBITORS MARKET: BY DRUGS, 2024
FIGURE 17 NORTH AMERICA CALCINEURIN INHIBITORS MARKET: BY DRUGS, 2025-2032 (USD MILLION)
FIGURE 18 NORTH AMERICA CALCINEURIN INHIBITORS MARKET: BY DRUGS, CAGR (2025-2032)
FIGURE 19 NORTH AMERICA CALCINEURIN INHIBITORS MARKET: BY DRUGS, LIFELINE CURVE
FIGURE 20 NORTH AMERICA CALCINEURIN INHIBITORS MARKET: BY DRUG TYPE,2024
FIGURE 21 NORTH AMERICA CALCINEURIN INHIBITORS MARKET: BY DRUG TYPE, 2025-2032 (USD MILLION)
FIGURE 22 NORTH AMERICA CALCINEURIN INHIBITORS MARKET: BY DRUG TYPE, CAGR (2025-2032)
FIGURE 23 NORTH AMERICA CALCINEURIN INHIBITORS MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 24 NORTH AMERICA CALCINEURIN INHIBITORS MARKET: BY APPLICATION, 2024
FIGURE 25 NORTH AMERICA CALCINEURIN INHIBITORS MARKET: BY APPLICATION, 2025-2032 (USD MILLION)
FIGURE 26 NORTH AMERICA CALCINEURIN INHIBITORS MARKET: BY APPLICATION, CAGR (2025-2032)
FIGURE 27 NORTH AMERICA CALCINEURIN INHIBITORS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 28 NORTH AMERICA CALCINEURIN INHIBITORS MARKET: BY ROUTE OF ADMINISTRATION, 2024
FIGURE 29 NORTH AMERICA CALCINEURIN INHIBITORS MARKET: BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
FIGURE 30 NORTH AMERICA CALCINEURIN INHIBITORS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2025-2032)
FIGURE 31 NORTH AMERICA CALCINEURIN INHIBITORS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 32 NORTH AMERICA CALCINEURIN INHIBITORS MARKET: BY END USER, 2024
FIGURE 33 NORTH AMERICA CALCINEURIN INHIBITORS MARKET: BY END USER, 2025-2032 (USD MILLION)
FIGURE 34 NORTH AMERICA CALCINEURIN INHIBITORS MARKET: BY END USER, CAGR (2025-2032)
FIGURE 35 NORTH AMERICA CALCINEURIN INHIBITORS MARKET: BY END USER, LIFELINE CURVE
FIGURE 36 NORTH AMERICA CALCINEURIN INHIBITORS MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 37 NORTH AMERICA CALCINEURIN INHIBITORS MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
FIGURE 38 NORTH AMERICA CALCINEURIN INHIBITORS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)
FIGURE 39 NORTH AMERICA CALCINEURIN INHIBITORS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 40 NORTH AMERICA CALCINEURIN INHIBITOR MARKET: SNAPSHOT (2024)
FIGURE 41 NORTH AMERICA CALCINEURIN INHIBITORS MARKET: COMPANY SHARE 2024 (%)
